A Real-Life Turkish Experience of Ruxolitinib in Polycythemia Vera
Introduction:Ruxolitinib is a small -molecule inhibitor of the JAK1/2 pathway. This study aimed to reveal the results and side-effect profile of the use of ruxolitinib as a treatment option in polycythemia vera (PV).Methods:A total of 34 patients with PV from 18 different centers were included in th...
| Main Authors: | , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Galenos Yayinevi
2023-05-01
|
| Series: | İstanbul Medical Journal |
| Subjects: | |
| Online Access: |
http://istanbulmedicaljournal.org/archives/archive-detail/article-preview/a-real-life-turkish-experience-of-ruxolitinib-in-p/60509
|
| _version_ | 1797813581587152896 |
|---|---|
| author | İstemi Serin Mehmet Hilmi Doğu Ömer Ekinci Gülsüm Akgün Çağlıyan Abdulkadir Baştürk Merih Reis Aras Sinan Demircioğlu Burhan Turgut Mustafa Merter Sibel Kabukçu Hacıoğlu Metin Bağcı Murat Albayrak Serdal Korkmaz Mehmet Ali Erkurt Mehmet Sinan Dal Fadime Ersoy Dursun Anıl Tombak İsmet Aydoğdu Turgay Ulaş Fevzi Altuntaş |
| author_facet | İstemi Serin Mehmet Hilmi Doğu Ömer Ekinci Gülsüm Akgün Çağlıyan Abdulkadir Baştürk Merih Reis Aras Sinan Demircioğlu Burhan Turgut Mustafa Merter Sibel Kabukçu Hacıoğlu Metin Bağcı Murat Albayrak Serdal Korkmaz Mehmet Ali Erkurt Mehmet Sinan Dal Fadime Ersoy Dursun Anıl Tombak İsmet Aydoğdu Turgay Ulaş Fevzi Altuntaş |
| author_sort | İstemi Serin |
| collection | DOAJ |
| description | Introduction:Ruxolitinib is a small -molecule inhibitor of the JAK1/2 pathway. This study aimed to reveal the results and side-effect profile of the use of ruxolitinib as a treatment option in polycythemia vera (PV).Methods:A total of 34 patients with PV from 18 different centers were included in the study. The evaluation of the response under treatment with ruxolitinib was determined as a reduction in spleen volume (splenomegaly size: ≥35%) by imaging and control of hematocrit levels (≤45%) compared to baseline.Results:While the number of patients in which a reduction in spleen volume and hematocrit control was achieved was 19 (55.9%) at 3 months of treatment, it was 21 (61.8%) at 6 months. Additionally, while the number of side effects was negatively correlated with the reduction in spleen volume (Spearman’s rho: -0.365, p=0.034), a decrease in the hematocrit level was positively correlated (Spearman’s rho: 0.75, p=0.029). Those without a reduction in spleen volume experienced more constipation (chi-square: 5.988, Fisher’s exact test: p=0.033).Conclusion:This study shed light on the use of ruxolitinib in PV and the importance of splenomegaly on studies planned with larger patient groups. |
| first_indexed | 2024-03-13T07:53:50Z |
| format | Article |
| id | doaj.art-2f9813f1062246cfa7c5bb2a592ed5f8 |
| institution | Directory Open Access Journal |
| issn | 2619-9793 2148-094X |
| language | English |
| last_indexed | 2024-03-13T07:53:50Z |
| publishDate | 2023-05-01 |
| publisher | Galenos Yayinevi |
| record_format | Article |
| series | İstanbul Medical Journal |
| spelling | doaj.art-2f9813f1062246cfa7c5bb2a592ed5f82023-06-02T07:03:31ZengGalenos Yayineviİstanbul Medical Journal2619-97932148-094X2023-05-0124212012510.4274/imj.galenos.2023.6674213049054A Real-Life Turkish Experience of Ruxolitinib in Polycythemia Veraİstemi Serin0Mehmet Hilmi Doğu1Ömer Ekinci2Gülsüm Akgün Çağlıyan3Abdulkadir Baştürk4Merih Reis Aras5Sinan Demircioğlu6Burhan Turgut7Mustafa Merter8Sibel Kabukçu Hacıoğlu9Metin Bağcı10Murat Albayrak11Serdal Korkmaz12Mehmet Ali Erkurt13Mehmet Sinan Dal14Fadime Ersoy Dursun15Anıl Tombak16İsmet Aydoğdu17Turgay Ulaş18Fevzi Altuntaş19 University of Health Sciences Turkey, İstanbul Training and Research Hospital, Clinic of Hematology, İstanbul, Turkey İstinye University, Liv Hospital Ulus, Clinic of Hematology, İstanbul, Turkey University of Health Sciences Turkey, Gazi Yaşargil Training and Research Hospital, Clinic of Hematology, Diyarbakır, Turkey Pamukkale University Faculty of Medicine, Department of Hematology, Denizli, Turkey Medicana International İstanbul Hospital, İstanbul, Turkey University of Health Sciences Turkey, Dışkapı Yıldırım Beyazıt Training and Research Hospital, Clinic of Hematology, Ankara, Turkey Necmettin Erbakan University, Meram Faculty of Medicine, Department of Hematology, Konya, Turkey Namık Kemal University Faculty of Medicine, Department of Hematology, Tekirdağ, Turkey Fırat University Faculty of Medicine, Department of Hematology, Elazığ, Turkey Pamukkale University Faculty of Medicine, Department of Hematology, Denizli, Turkey Selçuk University Faculty of Medicine, Department of Hematology, Konya, Turkey University of Health Sciences Turkey, Dışkapı Yıldırım Beyazıt Training and Research Hospital, Clinic of Hematology, Ankara, Turkey University of Health Sciences Turkey, Kayseri City Training and Research Hospital, Clinic of Hematology and Apheresis Unit, Kayseri, Turkey İnönü University Faculty of Medicine, Department of Hematology, Malatya, Turkey University of Health Sciences Turkey, Ankara Oncology Training and Research Hospital, Clinic of Hematology and Apheresis Unit, Ankara, Turkey İstanbul Medeniyet University, Göztepe Training and Research Hospital, Clinic of Hematology, İstanbul, Turkey Mersin University Faculty of Medicine, Department of Hematology, Mersin, Turkey Manisa Celal Bayar University Faculty of Medicine, Department of Hematology, Manisa, Turkey Near East University Faculty of Medicine, Department of Internal Medicine, Division of Hematology, Lefkoşa, Cyprus University of Health Sciences Turkey, Ankara Oncology Training and Research Hospital, Clinic of Hematology and Apheresis Unit, Ankara, Turkey Introduction:Ruxolitinib is a small -molecule inhibitor of the JAK1/2 pathway. This study aimed to reveal the results and side-effect profile of the use of ruxolitinib as a treatment option in polycythemia vera (PV).Methods:A total of 34 patients with PV from 18 different centers were included in the study. The evaluation of the response under treatment with ruxolitinib was determined as a reduction in spleen volume (splenomegaly size: ≥35%) by imaging and control of hematocrit levels (≤45%) compared to baseline.Results:While the number of patients in which a reduction in spleen volume and hematocrit control was achieved was 19 (55.9%) at 3 months of treatment, it was 21 (61.8%) at 6 months. Additionally, while the number of side effects was negatively correlated with the reduction in spleen volume (Spearman’s rho: -0.365, p=0.034), a decrease in the hematocrit level was positively correlated (Spearman’s rho: 0.75, p=0.029). Those without a reduction in spleen volume experienced more constipation (chi-square: 5.988, Fisher’s exact test: p=0.033).Conclusion:This study shed light on the use of ruxolitinib in PV and the importance of splenomegaly on studies planned with larger patient groups. http://istanbulmedicaljournal.org/archives/archive-detail/article-preview/a-real-life-turkish-experience-of-ruxolitinib-in-p/60509 polycythemia veraruxolitinibreal-life dataresponseside effect |
| spellingShingle | İstemi Serin Mehmet Hilmi Doğu Ömer Ekinci Gülsüm Akgün Çağlıyan Abdulkadir Baştürk Merih Reis Aras Sinan Demircioğlu Burhan Turgut Mustafa Merter Sibel Kabukçu Hacıoğlu Metin Bağcı Murat Albayrak Serdal Korkmaz Mehmet Ali Erkurt Mehmet Sinan Dal Fadime Ersoy Dursun Anıl Tombak İsmet Aydoğdu Turgay Ulaş Fevzi Altuntaş A Real-Life Turkish Experience of Ruxolitinib in Polycythemia Vera İstanbul Medical Journal polycythemia vera ruxolitinib real-life data response side effect |
| title | A Real-Life Turkish Experience of Ruxolitinib in Polycythemia Vera |
| title_full | A Real-Life Turkish Experience of Ruxolitinib in Polycythemia Vera |
| title_fullStr | A Real-Life Turkish Experience of Ruxolitinib in Polycythemia Vera |
| title_full_unstemmed | A Real-Life Turkish Experience of Ruxolitinib in Polycythemia Vera |
| title_short | A Real-Life Turkish Experience of Ruxolitinib in Polycythemia Vera |
| title_sort | real life turkish experience of ruxolitinib in polycythemia vera |
| topic | polycythemia vera ruxolitinib real-life data response side effect |
| url |
http://istanbulmedicaljournal.org/archives/archive-detail/article-preview/a-real-life-turkish-experience-of-ruxolitinib-in-p/60509
|
| work_keys_str_mv | AT istemiserin areallifeturkishexperienceofruxolitinibinpolycythemiavera AT mehmethilmidogu areallifeturkishexperienceofruxolitinibinpolycythemiavera AT omerekinci areallifeturkishexperienceofruxolitinibinpolycythemiavera AT gulsumakguncaglıyan areallifeturkishexperienceofruxolitinibinpolycythemiavera AT abdulkadirbasturk areallifeturkishexperienceofruxolitinibinpolycythemiavera AT merihreisaras areallifeturkishexperienceofruxolitinibinpolycythemiavera AT sinandemircioglu areallifeturkishexperienceofruxolitinibinpolycythemiavera AT burhanturgut areallifeturkishexperienceofruxolitinibinpolycythemiavera AT mustafamerter areallifeturkishexperienceofruxolitinibinpolycythemiavera AT sibelkabukcuhacıoglu areallifeturkishexperienceofruxolitinibinpolycythemiavera AT metinbagcı areallifeturkishexperienceofruxolitinibinpolycythemiavera AT muratalbayrak areallifeturkishexperienceofruxolitinibinpolycythemiavera AT serdalkorkmaz areallifeturkishexperienceofruxolitinibinpolycythemiavera AT mehmetalierkurt areallifeturkishexperienceofruxolitinibinpolycythemiavera AT mehmetsinandal areallifeturkishexperienceofruxolitinibinpolycythemiavera AT fadimeersoydursun areallifeturkishexperienceofruxolitinibinpolycythemiavera AT anıltombak areallifeturkishexperienceofruxolitinibinpolycythemiavera AT ismetaydogdu areallifeturkishexperienceofruxolitinibinpolycythemiavera AT turgayulas areallifeturkishexperienceofruxolitinibinpolycythemiavera AT fevzialtuntas areallifeturkishexperienceofruxolitinibinpolycythemiavera AT istemiserin reallifeturkishexperienceofruxolitinibinpolycythemiavera AT mehmethilmidogu reallifeturkishexperienceofruxolitinibinpolycythemiavera AT omerekinci reallifeturkishexperienceofruxolitinibinpolycythemiavera AT gulsumakguncaglıyan reallifeturkishexperienceofruxolitinibinpolycythemiavera AT abdulkadirbasturk reallifeturkishexperienceofruxolitinibinpolycythemiavera AT merihreisaras reallifeturkishexperienceofruxolitinibinpolycythemiavera AT sinandemircioglu reallifeturkishexperienceofruxolitinibinpolycythemiavera AT burhanturgut reallifeturkishexperienceofruxolitinibinpolycythemiavera AT mustafamerter reallifeturkishexperienceofruxolitinibinpolycythemiavera AT sibelkabukcuhacıoglu reallifeturkishexperienceofruxolitinibinpolycythemiavera AT metinbagcı reallifeturkishexperienceofruxolitinibinpolycythemiavera AT muratalbayrak reallifeturkishexperienceofruxolitinibinpolycythemiavera AT serdalkorkmaz reallifeturkishexperienceofruxolitinibinpolycythemiavera AT mehmetalierkurt reallifeturkishexperienceofruxolitinibinpolycythemiavera AT mehmetsinandal reallifeturkishexperienceofruxolitinibinpolycythemiavera AT fadimeersoydursun reallifeturkishexperienceofruxolitinibinpolycythemiavera AT anıltombak reallifeturkishexperienceofruxolitinibinpolycythemiavera AT ismetaydogdu reallifeturkishexperienceofruxolitinibinpolycythemiavera AT turgayulas reallifeturkishexperienceofruxolitinibinpolycythemiavera AT fevzialtuntas reallifeturkishexperienceofruxolitinibinpolycythemiavera |